Pay what you want · $12.99 minimum
Instant EPUB download — reads on Kindle,
Apple Books, Kobo, Google Play & more
A Science-Backed Comparison of Retatrutide, Semaglutide & Tirzepatide
Three drugs, one decision — and the internet is either a sales pitch or a wall of jargon. This is the version written for the actual decision in front of you.
What's inside
- How these drugs actually work — single-, dual-, and triple-receptor agonism, explained plainly
- The trial data, side by side — real figures from the named trials, with honest caveats
- Side effects and safety, class by class
- What's available today — realistic cost, insurance, and timelines
- The compounding reality, addressed directly — the risks, with zero how-to and zero sourcing
- A real decision framework — built around your urgency, risk tolerance, and access
122 pages · ~26,700 words · a focused 2–3 hour read. Every clinical figure checked against the primary sources.
Please read: This book is educational and is not medical advice. Retatrutide is an investigational medication in Phase 3 clinical trials and is not FDA-approved. Semaglutide and tirzepatide are FDA-approved prescription medications. Nothing here is a guide to obtaining or starting any medication — those decisions belong to you and a qualified healthcare provider. Brand names are the property of their respective owners and are used for identification and comparison only; the author is not affiliated with, sponsored by, or endorsed by them.
